A molecular diagnostics company developed a blood test to support treatment selection for patients with advanced non-small cell lung cancer (NSCLC). While many patients with EGFR-mutated, PDL-1 expressing NSCLC respond to immune checkpoint inhibitors (ICIS), many do not. An unmet medical need existed for a more precise test to determine which patients with this tumor type would respond to ICIS. The client's blood test purported to predict patient response to ICIS.
Explore how Datavant can be your health data logistics partner.Contact us